{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:42:18Z","timestamp":1793644938451,"version":"4.5.1"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI165072"],"award-info":[{"award-number":["P01AI165072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI170715"],"award-info":[{"award-number":["R01AI170715"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI165524"],"award-info":[{"award-number":["U01AI165524"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI164566"],"award-info":[{"award-number":["UM1AI164566"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR080659"],"award-info":[{"award-number":["R01AR080659"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI135995"],"award-info":[{"award-number":["U19AI135995"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For endemically circulating viruses, quantifying neutralization capacity of antibodies in a rapid and high-throughput manner is paramount given the ever-evolving targets of neutralization. Moreover, identifying features of an antibody response correlating with neutralization at the multivariate level can inform vaccine boosting strategies and next-generation monoclonal antibody therapies. In this study, we developed a systems-predicted neutralizing antibody platform that is capable of quantifying neutralization capacity at the multiplex level. We validated the platform using SARS-CoV-2 ancestral and highly diverged Omicron sublineage spikes simultaneously. Combining these results with a broader systems serology approach identified humoral signatures that predict broadly neutralizing responses that are divergent between vaccine or hybrid immunity. In both cases, though, predicted neutralization responses were enmeshed in antibody networks, showing that target-specific and broadly neutralizing antibody responses are multi-isotype- and subclass-influenced. We propose that neutralization against a diverse array of viral receptor-binding proteins can be quantified using a systems-based platform in a sample- and time-sparing approach, which can be further employed to predict protection against newly emerged viruses or variants.<\/jats:p>","DOI":"10.1093\/jimmun\/vkag106","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:38:47Z","timestamp":1779705527000},"source":"Crossref","is-referenced-by-count":1,"title":["A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors"],"prefix":"10.1093","volume":"215","author":[{"given":"Qixin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay R","family":"McManus","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate S","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Blanc","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Malca","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1022-9450","authenticated-orcid":false,"given":"Brian A","family":"Joughin","sequence":"additional","affiliation":[{"name":"Department of Biological Engineering, Massachusetts Institute of Technology , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Bi","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Division of Genetics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Keerti","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Division of Genetics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-989X","authenticated-orcid":false,"given":"Douglas A","family":"Lauffenburger","sequence":"additional","affiliation":[{"name":"Department of Biological Engineering, Massachusetts Institute of Technology , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-944X","authenticated-orcid":false,"given":"Duane R","family":"Wesemann","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Division of Genetics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA,","place":["United States"]},{"name":"Ragon Institute of Mass General, MIT, and Harvard , Cambridge, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8866-3532","authenticated-orcid":false,"given":"Ryan P","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2026090708272103900_vkag106-B1","doi-asserted-by":"crossref","first-page":"e0303623","DOI":"10.1128\/mbio.03036-23","article-title":"Understanding Fc function for rational vaccine design against pathogens","volume":"15","author":"Bowman","year":"2024","journal-title":"mBio"},{"key":"2026090708272103900_vkag106-B2","doi-asserted-by":"crossref","first-page":"1430955","DOI":"10.3389\/fimmu.2024.1430955","article-title":"Antibodies as key mediators of protection against","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"2026090708272103900_vkag106-B3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fimmu.2019.00440","article-title":"Extra-neutralizing FcR-mediated antibody functions for a universal influenza vaccine","volume":"10","author":"Boudreau","year":"2019","journal-title":"Front Immunol"},{"key":"2026090708272103900_vkag106-B4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3389\/fimmu.2019.01851","article-title":"A sample-sparing multiplexed ADCP assay","volume":"10","author":"Butler","year":"2019","journal-title":"Front Immunol"},{"key":"2026090708272103900_vkag106-B5","doi-asserted-by":"crossref","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"Fischinger","year":"2019","journal-title":"J Immunol Methods"},{"key":"2026090708272103900_vkag106-B6","doi-asserted-by":"crossref","first-page":"e1005315","DOI":"10.1371\/journal.ppat.1005315","article-title":"Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control","volume":"12","author":"Ackerman","year":"2016","journal-title":"PLoS Pathog"},{"key":"2026090708272103900_vkag106-B7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"2026090708272103900_vkag106-B9","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090708272103900_vkag106-B10","doi-asserted-by":"crossref","first-page":"11157","DOI":"10.1073\/pnas.1708727114","article-title":"Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion","volume":"114","author":"Walls","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090708272103900_vkag106-B11","doi-asserted-by":"crossref","first-page":"102768","DOI":"10.1016\/j.ebiom.2020.102768","article-title":"Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development","volume":"55","author":"de Alwis","year":"2020","journal-title":"EBioMedicine"},{"key":"2026090708272103900_vkag106-B12","doi-asserted-by":"crossref","first-page":"1609779","DOI":"10.3389\/fimmu.2025.1609779","article-title":"Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3","volume":"16","author":"Tong","year":"2025","journal-title":"Front Immunol"},{"key":"2026090708272103900_vkag106-B13","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms","volume":"19","author":"Nagy","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"2026090708272103900_vkag106-B14","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2026090708272103900_vkag106-B15","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B16","doi-asserted-by":"crossref","first-page":"114684","DOI":"10.1016\/j.celrep.2024.114684","article-title":"SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner","volume":"43","author":"Jung","year":"2024","journal-title":"Cell Rep"},{"key":"2026090708272103900_vkag106-B17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/infdis\/jiad353","article-title":"SARS-CoV-2 hybrid immunity: the best of both worlds","volume":"228","author":"Lasrado","year":"2023","journal-title":"J Infect Dis"},{"key":"2026090708272103900_vkag106-B18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic Omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B19","doi-asserted-by":"crossref","first-page":"e0164722","DOI":"10.1128\/mbio.01647-22","article-title":"Hybrid immunity shifts the Fc-effector quality of SARS-CoV-2 mRNA vaccine-induced immunity","volume":"13","author":"Bowman","year":"2022","journal-title":"mBio"},{"key":"2026090708272103900_vkag106-B20","doi-asserted-by":"crossref","first-page":"eabn8014","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"key":"2026090708272103900_vkag106-B21","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A Covid-19 milestone attained\u2014a correlate of protection for vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B22","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1038\/s41467-025-61153-x","article-title":"Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial","volume":"16","author":"Ma","year":"2025","journal-title":"Nat Commun"},{"key":"2026090708272103900_vkag106-B23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1586\/14760584.2016.1164046","article-title":"Influenza immunology evaluation and correlates of protection: a focus on vaccines","volume":"15","author":"Trombetta","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2026090708272103900_vkag106-B24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2026090708272103900_vkag106-B25","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026090708272103900_vkag106-B26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMc2214314","article-title":"Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1","volume":"388","author":"Miller","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41467-023-36561-6","article-title":"Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies","volume":"14","author":"Planas","year":"2023","journal-title":"Nat Commun"},{"key":"2026090708272103900_vkag106-B28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"2026090708272103900_vkag106-B29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1473-3099(23)00278-5","article-title":"Virological characteristics of the SARS-CoV-2 Omicron XBB.1.16 variant","volume":"23","author":"Yamasoba","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026090708272103900_vkag106-B30","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1038\/s41467-023-38435-3","article-title":"Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants","volume":"14","author":"Tamura","year":"2023","journal-title":"Nat Commun"},{"key":"2026090708272103900_vkag106-B31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026090708272103900_vkag106-B32","doi-asserted-by":"crossref","first-page":"eadg7015","DOI":"10.1126\/sciimmunol.adg7015","article-title":"Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates","volume":"8","author":"Routhu","year":"2023","journal-title":"Sci Immunol"},{"key":"2026090708272103900_vkag106-B33","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-023-41537-7","article-title":"mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States","volume":"14","author":"Tseng","year":"2023","journal-title":"Nat Commun"},{"key":"2026090708272103900_vkag106-B34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"2026090708272103900_vkag106-B35","doi-asserted-by":"crossref","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, Covid-19 from Omicron, Delta, and Alpha SARS-CoV-2 variants in the United States: prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"2026090708272103900_vkag106-B36","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa","volume":"28","author":"Tegally","year":"2022","journal-title":"Nat Med"},{"key":"2026090708272103900_vkag106-B37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an Omicron XBB.1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026090708272103900_vkag106-B38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2215471","article-title":"Effectiveness of bivalent boosters against severe Omicron infection","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B39","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMc2302462","article-title":"Durability of bivalent boosters against Omicron subvariants","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s43856-023-00302-z","article-title":"Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters","volume":"3","author":"Berry","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"2026090708272103900_vkag106-B41","doi-asserted-by":"crossref","first-page":"113292","DOI":"10.1016\/j.celrep.2023.113292","article-title":"Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines","volume":"42","author":"Deng","year":"2023","journal-title":"Cell Rep"},{"key":"2026090708272103900_vkag106-B42","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41467-023-36908-z","article-title":"Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates","volume":"14","author":"Pavot","year":"2023","journal-title":"Nat Commun"},{"key":"2026090708272103900_vkag106-B43","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.chom.2024.10.016","article-title":"A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice","volume":"32","author":"Case","year":"2024","journal-title":"Cell Host Microbe"},{"key":"2026090708272103900_vkag106-B44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41541-023-00665-3","article-title":"Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection","volume":"8","author":"Diallo","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026090708272103900_vkag106-B45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"2026090708272103900_vkag106-B46","doi-asserted-by":"crossref","first-page":"eabn9243","DOI":"10.1126\/scitranslmed.abn9243","article-title":"Omicron variant spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines","volume":"14","author":"Bartsch","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026090708272103900_vkag106-B47","doi-asserted-by":"crossref","first-page":"e0090223","DOI":"10.1128\/mbio.00902-23","article-title":"Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern","volume":"14","author":"McNamara","year":"2023","journal-title":"mBio"},{"key":"2026090708272103900_vkag106-B48","doi-asserted-by":"crossref","first-page":"eabp8328","DOI":"10.1126\/sciimmunol.abp8328","article-title":"Immune recall improves antibody durability and breadth to SARS-CoV-2 variants","volume":"7","author":"Chen","year":"2022","journal-title":"Sci Immunol"},{"key":"2026090708272103900_vkag106-B49","doi-asserted-by":"crossref","first-page":"e00750-20","DOI":"10.1128\/JCM.00750-20","article-title":"Comparability of titers of antibodies against seasonal influenza virus strains as determined by hemagglutination inhibition and microneutralization assays","volume":"58","author":"Heeringa","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2026090708272103900_vkag106-B50","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1038\/s41467-023-39189-8","article-title":"Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination","volume":"14","author":"Tong","year":"2023","journal-title":"Nat Commun"},{"key":"2026090708272103900_vkag106-B51","doi-asserted-by":"crossref","first-page":"115709","DOI":"10.1016\/j.celrep.2025.115709","article-title":"Acute infectious mononucleosis generates persistent, functional EBNA-1 antibodies with high cross-reactivity to alpha-crystalline beta","volume":"44","author":"Ganta","year":"2025","journal-title":"Cell Rep"},{"key":"2026090708272103900_vkag106-B52","article-title":"Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial","author":"Branche","year":"2023","journal-title":"Res Sq"},{"key":"2026090708272103900_vkag106-B53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"2026090708272103900_vkag106-B54","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090708272103900_vkag106-B55","doi-asserted-by":"publisher","author":"Tong","year":"2024","DOI":"10.1101\/2024.10.17.24315607"},{"key":"2026090708272103900_vkag106-B56","doi-asserted-by":"crossref","first-page":"101048","DOI":"10.1016\/j.xcrm.2023.101048","article-title":"Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines","volume":"4","author":"Kaplonek","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026090708272103900_vkag106-B57","doi-asserted-by":"crossref","first-page":"100405","DOI":"10.1016\/j.xcrm.2021.100405","article-title":"Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination","volume":"2","author":"Gorman","year":"2021","journal-title":"Cell Rep Med"},{"key":"2026090708272103900_vkag106-B58","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1080\/21645515.2021.1976580","article-title":"Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection","volume":"17","author":"Gunn","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2026090708272103900_vkag106-B59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/COH.0000000000000644","article-title":"Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV","volume":"15","author":"Danesh","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"2026090708272103900_vkag106-B60","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090708272103900_vkag106-B61","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease","volume":"10","author":"van Erp","year":"2019","journal-title":"Front Immunol"},{"key":"2026090708272103900_vkag106-B62","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology","volume":"163","author":"Chung","year":"2015","journal-title":"Cell"},{"key":"2026090708272103900_vkag106-B63","doi-asserted-by":"crossref","first-page":"eadu7646","DOI":"10.1126\/scitranslmed.adu7646","article-title":"Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques","volume":"17","author":"Jacob-Dolan","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026090708272103900_vkag106-B64","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-023-06951-3","article-title":"Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques","volume":"626","author":"McMahan","year":"2024","journal-title":"Nature"},{"key":"2026090708272103900_vkag106-B65","doi-asserted-by":"crossref","first-page":"110174","DOI":"10.1016\/j.isci.2024.110174","article-title":"Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques","volume":"27","author":"Tong","year":"2024","journal-title":"iScience"},{"key":"2026090708272103900_vkag106-B66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2017.01.010","article-title":"Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles","volume":"443","author":"Brown","year":"2017","journal-title":"J Immunol Methods"},{"key":"2026090708272103900_vkag106-B67","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4161\/mabs.28808","article-title":"Highly parallel characterization of IgG Fc binding interactions","volume":"6","author":"Boesch","year":"2014","journal-title":"MAbs"},{"key":"2026090708272103900_vkag106-B68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jim.2012.09.007","article-title":"High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples","volume":"386","author":"Brown","year":"2012","journal-title":"J Immunol Methods"},{"key":"2026090708272103900_vkag106-B69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4049\/jimmunol.2200956","article-title":"Distinct functional humoral immune responses are induced after live attenuated and inactivated seasonal influenza vaccination","volume":"212","author":"Tong","year":"2024","journal-title":"J Immunol"},{"key":"2026090708272103900_vkag106-B70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/10543400701668290","article-title":"Overview of agreement statistics for medical devices","volume":"18","author":"Lin","year":"2008","journal-title":"J Biopharm Stat"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/215\/5\/vkag106\/68380736\/vkag106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/215\/5\/vkag106\/68380736\/vkag106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:27:37Z","timestamp":1788784057000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/doi\/10.1093\/jimmun\/vkag106\/8692555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkag106","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"vkag106"}}